Clinical Trial Update: A Single-Dose Open-Label Study of XOMA 358 in Subjects With Congenital Hyperinsulinism [Phase 2]

View source ↗

Summary

A Phase 2, single-dose, open-label study of XOMA 358 in subjects with congenital hyperinsulinism has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Congenital Hyperinsulinism

Drugs mentioned

• XOMA 358

Snippet

Sponsor: XOMA (US) LLC | Conditions: Congenital Hyperinsulinism | Phase 2 | Status: COMPLETED